Faruk Recep Özalp

6PUBLICATIONS
48CO-AUTHORS
Nutrigenomics and personalised nutritionPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 26, 2026
Prognostic Value of the Modified Glasgow Prognostic Score in Patients with Metastatic Renal Cell Carcinoma Receiving Nivolumab as Second-Line Therapy: A Multicentre Retrospective Cohort Study.

|Sep 15, 2026
OX40 (TNFRSF4) Tracks Immune Infiltration in Small Cell Lung Cancer and Shows a Cohort-Specific, Non-Replicated Association with the POU2F3/SCLC-P Subtype: A Multi-Source In Silico Analysis.

|May 27, 2026
First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis.

|May 25, 2026
Integrative in silico transcriptomic and pharmacogenomic analysis of CD276 as a candidate prognostic biomarker and therapeutic target in bladder cancer.

|Sep 27, 2025
Evaluation of the Meet-URO Score in a Real-World Cohort of mRCC Patients Treated with First-Line TKIs.

Faruk Recep Özalp, Ece Şahin Hafızoğlu, Ahmet Melih Arslan

|Nov 29, 2024
Prognostic value of B7-H3 expression in metastatic renal cell carcinoma and its impact on immunotherapy response.

Faruk Recep Özalp, Kutsal Yörükoğlu, Eda Çalışkan Yıldırım

Pageof 1

Frequent Collaborators

3 joint publications

Sedat Biter

3 joint publications

Hüseyin Salih Semiz

2 joint publications

Ahmet Melih Arslan

2 joint publications

Mehmet Uzun